The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 439-446

  Eiermann, Birgit ^a   Engel, Georg ^b,d   Johansson, Inger ^c   Zanger, Ulrich M ^d   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Clozapine; CYP1A2; CYP3A4; Human liver microsomes

Indexed keywords

ANTIBODY; CLOZAPINE; CYTOCHROME P450 ISOENZYME; FLUVOXAMINE; KETOCONAZOLE; QUINIDINE; TROLEANDOMYCIN;

ARTICLE; DEMETHYLATION; DRUG METABOLISM; DRUG MONITORING; DRUG OXIDATION; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL;

EID: 0030656425     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00605.x     Document Type: Article

References (38)

1. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990; 5: 722-747.
2. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746-754.
3. Alvir JMJ, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. J Clin Psychopharmacol 1994; 14: 87-89.
4. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokin 1993; 24: 161-176.
5. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: A review of recent literature. J Clin Psychopharmacol 1996; 16: 177-187.
6. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 14: 119-125.
7. Bertilsson L, Dahl ML. Polymorphic drug oxidation-Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-223.
8. Fischer V, Vogels B, Maurer G, Tynes RE. The anripsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992; 260: 1355-1360.
9. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995; 272: 984-990.
10. Dahl ML, Llerena A, Bondesson U, Lindström L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71-74.
11. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from therapeutic drug monitoring service. Ther Drug Monit 1994; 37: 368-374.
12. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated plasma levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-281.
13. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
14. Haring C, Meise U, Humpel C, Sana A, Fleischhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine; influence of smoking behaviour, sex and age. Psychopharmacol 1989; 99: S38-S40.
15. Bertilsson L, Carrillo JA, Dahl ML et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
16. Moreland TA, Park BK, Rylance GW. Microsomal enzyme induction in children: The influence of carbamazepine treatment on antipyrine kinetics, 6β-hydroxycortisol excretion and plasma γ-glutanyltranspeptidase activity. Br J Clin Pharmacol 1982; 14: 861-865.
17. von Bahr C, Groth C-G, Jansson H, Lundgren G, Lind M, Glauman H. Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 1980; 27: 711-725.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent: J Biol Chem 1951; 193: 265-275.
19. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
20. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsu M. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681-693.
21. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
22. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 27: 8256-8260.
23. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Clin Pharmacokinet 1994; 26: 59-70.
24. Belloc C, Baird S, Cosine J, et al. Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 1996; 106: 207-219.
25. 5. Gene 1993; 125: 49-55.
26. Urban P, Cullin C, Pompon D. Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. Biochimie 1990; 72: 463-472.
27. Cullin C, Pompon D. Synthesis of functional mouse cytochromes P-450 P1 and chimeric P-450 P3-1 in the yeast of Saccaromyces cerevisae. Gene 1988; 65: 203-217.
28. Bellamine A, Gautier JC, Urban P, Pompon D. Chimeras of the human cytochrome P450 IA family produced in yeast. Accumulation in microsomal membranes, enzyme kinetics and stability. Eur J Biochem 1994; 225: 1005-1013.
29. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes, J Biol Chem 1964; 239: 2370-2378.
30. Burke MD, Mayer RT. Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450 -binding of phenoxazone and a homologous series of its n-alkyl-ethers (alkoxyresorufins). Chem Biol Interactions 1983; 45: 243-258.
31. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK. N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 1997; 25: 524-527.
32. Rodrigues AD. Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 1994; 48: 2147-2156.
33. Edge SC, Markowitz JS, Devane CL. Clozapine drug-drug interactions: a review of the literature. Human Psychopharmacol 1997; 12: 5-20.
34. Carillo JA, Jerling M, Bertilsson L. Comments to 'Interaction between caffeine and Clozapine'. J Clin Psychopharmacol 1995; 15: 376-377.
35. Guengerich FP. Mechanisms of catalysis and substrate specificity of human cytochrome P450 enzymes. Falk Symp 1991; 57: 85-96.
36. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 38: 399-403.
37. Carnllo JA, Dahl ML, Svensson JO, Aim C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity, Clin Pharmacol Ther 1996; 60: 183-190.
38. Glassner Cohen L, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996; 156: 675-677.